National Drug Control Policy Office – Federal Register Recent Federal Regulation Documents

Freedom of Information Act
Document Number: 2020-20270
Type: Rule
Date: 2020-10-16
Agency: National Drug Control Policy Office, Executive Office of the President
The Office of National Drug Control Policy (ONDCP) is updating its Freedom of Information Act (FOIA) implementing regulation to comport with the FOIA Improvement Act of 2016 and best practices. The final rule describes how to make a FOIA request with ONDCP and how the Office of General Counsel, which includes the ONDCP officials authorized to evaluate FOIA requests, processes requests for records. The final rule also states ONDCP's Privacy Act Policies and Procedures. The final rule describes how individuals can learn if an ONDCP system of records contains information about them and, if so, how to access or amend a record.
Appointment of Members of Senior Executive Service Performance Review Board
Document Number: 2020-15491
Type: Notice
Date: 2020-07-17
Agency: Executive Office of the President, National Drug Control Policy Office
The following persons have been appointed to the ONDCP Senior Executive Service Performance Review Board: Ms. Martha Gagn[eacute] (as Chair), Mr. Kemp Chester, Mr. Eric Talbot, and Dr. Terry Zobeck.
Designation of Three Areas as High Intensity Drug Trafficking Areas
Document Number: 2020-12658
Type: Notice
Date: 2020-06-11
Agency: Executive Office of the President, National Drug Control Policy Office
The Director of the Office of National Drug Control Policy designated 3 additional areas as High Intensity Drug Trafficking Areas (HIDTA).
Designation of Twelve Areas as High Intensity Drug Trafficking Areas
Document Number: 2020-12105
Type: Notice
Date: 2020-06-04
Agency: Executive Office of the President, National Drug Control Policy Office
The Director of the Office of National Drug Control Policy designated 12 additional areas as High Intensity Drug Trafficking Areas (HIDTA) pursuant to 21 U.S.C. 1706(b)(1). The new areas are (1) Davidson County in Tennessee as part of the Appalachia HIDTA; (2) Chatham County in Georgia as part of the Atlanta/Carolinas HIDTA; (3) Manatee and Leon Counties in Florida as part of the Central Florida and North Florida HIDTAs, respectively; (4) Lake County in Illinois as part of the Chicago HIDTA; (5) Chambers County in Texas as part of the Houston HIDTA; (6) Vanderburgh County in Indiana as part of the Indiana HIDTA; (7) Eau Claire County in Wisconsin as part of the North Central HIDTA; (8) Grant County in Washington as part of the Northwest HIDTA; (9) Westmoreland County in Pennsylvania as part of the Ohio HIDTA; (10) Kootenai County in Idaho as part of the Oregon/Idaho HIDTA; and (11) Allegany County in Maryland as part of the Washington/Baltimore HIDTA. The Director of ONDCP also removed one area as a HIDTA pursuant to 21 U.S.C. 1706(c), effective May 27, 2020. The area removed from HIDTA designation is Barrow County in Georgia as part of the Atlanta/ Carolinas HIDTA. The Executive Board of Atlanta/Carolinas HIDTA requested removal of Barrow County from designation after assessing the threat and determining that it no longer met the statutory criteria necessary for designation as a HIDTA county. ONDCP evaluated and accepted the request.
Freedom of Information Act
Document Number: 2020-09826
Type: Proposed Rule
Date: 2020-05-22
Agency: Executive Office of the President, National Drug Control Policy Office
The Office of National Drug Control Policy (ONDCP) is updating its Freedom of Information Act (FOIA) implementing regulation to comport with the FOIA Improvement Act of 2016 and best practices. The proposed rule describes how to make a FOIA request with ONDCP and how the Office of General Counsel, which includes the ONDCP officials authorized to evaluate FOIA requests, processes requests for records. The proposed rule also states ONDCP's Privacy Act Policies and Procedures. The proposed rule describes how individuals can find out if an ONDCP system of records contains information about them and, if so, how to access or amend a record. ONDCP seeks comments on all aspects of the proposed rule and will thoroughly consider all comments that are submitted on time.
Criteria for Designation of Emerging Drug Threats in the United States
Document Number: 2020-09469
Type: Proposed Rule
Date: 2020-05-15
Agency: Executive Office of the President, National Drug Control Policy Office
The Office of National Drug Control Policy is announcing this Advance Notice of Proposed Rulemaking (ANPRM) and requests information relevant to criteria for designating and terminating the designation of emerging drug threats in the United States pursuant to the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act). This ANPRM briefly summarizes the White House Office of National Drug Control Policy's (ONDCP) ongoing work in this area and describes the criteria that ONDCP is considering to monitor and identify emerging drug threats. The ANPRM invites interested parties to submit comments, data, and other pertinent information concerning ONDCP's development of proposed criteria for designating emerging drug threats and terminating such designations.
Submission for Review: Survey on Practices and Policies Related to the Treatment of Opioid Use Disorders; Correction
Document Number: 2019-27709
Type: Notice
Date: 2019-12-26
Agency: Executive Office of the President, National Drug Control Policy Office
The Office of National Drug Control Policy published a document in the Federal Register on December 12, 2019 concerning the Paperwork Reduction Act; Proposed Collection; Comment Request. The document contained an incorrect address and contact information.
Submission for Review: Survey on the Treatment of Opioid Use Disorders; Correction
Document Number: 2019-27708
Type: Notice
Date: 2019-12-26
Agency: Executive Office of the President, National Drug Control Policy Office
The Office of National Drug Control Policy published a document in the Federal Register on December 12, 2019 concerning the Paperwork Reduction Act; Proposed Collection; Comment Request. The document contained an incorrect address and contact information.
Submission for Review: Survey on Practices and Policies Related to the Treatment of Opioid Use Disorders
Document Number: 2019-26803
Type: Notice
Date: 2019-12-12
Agency: Executive Office of the President, National Drug Control Policy Office
In accordance with the Paperwork Reduction Act of 1995, the Office of National Drug Control Policy (ONDCP) announces it will submit to the Office of Management and Budget (OMB) and Office of Information and Regulatory Affairs (OIRA) an information collection request. This proposed information collection was previously published in the Federal Register of October 8, 2019 and allowed 60 days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment.
Submission for Review: Survey on the Treatment of Opioid Use Disorders
Document Number: 2019-26793
Type: Notice
Date: 2019-12-12
Agency: Executive Office of the President, National Drug Control Policy Office
In accordance with the Paperwork Reduction Act of 1995, the Office of National Drug Control Policy (ONDCP) announces it will submit to the Office of Management and Budget (OMB) and Office of Information and Regulatory Affairs (OIRA) an information collection request. This proposed information collection was previously published in the Federal Register of October 8, 2019 and allowed 60 days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment.
Submission for Review: Survey on Practices and Policies Related to the Treatment of Opioid Use Disorders
Document Number: 2019-21921
Type: Notice
Date: 2019-10-08
Agency: Executive Office of the President, National Drug Control Policy Office
In accordance with the Paperwork Reduction Act of 1995, the Office of National Drug Control Policy (ONDCP) announces it will submit to the Office of Management and Budget (OMB) and Office of Information and Regulatory Affairs (OIRA) an information collection request.
Submission for Review: Survey on the Treatment of Opioid Use Disorders
Document Number: 2019-21919
Type: Notice
Date: 2019-10-08
Agency: Executive Office of the President, National Drug Control Policy Office
In accordance with the Paperwork Reduction Act of 1995, the Office of National Drug Control Policy (ONDCP) announces it will submit to the Office of Management and Budget (OMB) and Office of Information and Regulatory Affairs (OIRA) an information collection request.
Designation of Eleven Areas as High Intensity Drug Trafficking Areas
Document Number: 2019-19661
Type: Notice
Date: 2019-09-11
Agency: Executive Office of the President, National Drug Control Policy Office
The Director of the Office of National Drug Control Policy designated 13 additional areas as High Intensity Drug Trafficking Areas (HIDTA) pursuant to 21 U.S.C. 1706(b)(1). The new areas are (1) Anderson County in Tennessee, Boyd County in Kentucky, and Fayette County in West Virginia as part of the Appalachia HIDTA; (2) Floyd County in Georgia as part of the Atlanta/Carolinas HIDTA; (3) Allen County in Indiana as part of the Indiana HIDTA (4) Gloucester County in New Jersey and Bucks County in Pennsylvania as part of the Liberty Mid- Atlantic HIDTA; (5) Oswego County in New York as part of the New York/ New Jersey HIDTA; (6) Olmsted and St. Louis Counties in Minnesota as part of the North Central HIDTA (7) Josephine County in Oregon as part of the Oregon/Idaho HIDTA and (8) Worcester County in Maryland and Warren County in Virginia as part of the Washington/Baltimore HIDTA. The Director of ONDCP also removed six areas as HIDTAs pursuant to 21 U.S.C. 1706(c), effective September 10, 2019. The six areas removed from HIDTA designation are (1) Breathitt and McCreary Counties in Kentucky and Macon and Unicoi Counties in Tennessee as part of the Appalachia HIDTA; (2) Marion County in Missouri as part of the Midwest HIDTA; and (3) the Confederated Tribe of Warm Springs Reservation in Oregon as part of the Oregon-Idaho HIDTA. The Executive Boards of each of these HIDTAs requested removal of these areas from designation after assessing the threat and determining that these areas no longer met the statutory criteria necessary for designation as HIDTA counties. ONDCP evaluated and accepted the request.
Appointment of Members of Senior Executive Service Performance Review Board
Document Number: 2019-19077
Type: Notice
Date: 2019-09-04
Agency: National Drug Control Policy Office, Executive Office of the President
The following persons have been appointed to the ONDCP Senior Executive Service Performance Review Board: Ms. Martha Gagn[eacute] (as Chair), Mr. Kemp Chester, Mr. Michael Gottlieb, and Dr. Terry Zobeck.
Paperwork Reduction Act; Proposed Collection; Comment Request
Document Number: 2019-15303
Type: Notice
Date: 2019-07-18
Agency: Executive Office of the President, National Drug Control Policy Office
In accordance with the Paperwork Reduction Act of 1995, the Office of National Drug Control Policy (ONDCP) announces it will submit to the Office of Management and Budget (OMB) and Office of Information and Regulatory Affairs (OIRA) an information collection request. The purpose of this notice is to allow for an additional 30 days of public comment.
Paperwork Reduction Act; Proposed Collection; Comment Request
Document Number: 2019-09553
Type: Notice
Date: 2019-05-09
Agency: Executive Office of the President, National Drug Control Policy Office
In accordance with the Paperwork Reduction Act of 1995, the Office of National Drug Control Policy (ONDCP) announces it will submit to the Office of Management and Budget (OMB) and Office of Information and Regulatory Affairs (OIRA) an information collection request.
Designation of 10 Areas as High Intensity Drug Trafficking Areas
Document Number: 2018-22462
Type: Notice
Date: 2018-10-16
Agency: Executive Office of the President, National Drug Control Policy Office
The Director of the Office of National Drug Control Policy designated 10 additional areas as High Intensity Drug Trafficking Areas (HIDTA) pursuant to 21 U.S.C. 1706. The new areas are (1) Montgomery and Powell Counties in Kentucky as part of the Appalachia HIDTA; (2) Charleston County in South Carolina and the Eastern Band of Cherokee Indian Reservation as part of the Atlanta/Carolinas HIDTA; (3) Atlantic County in New Jersey as part of the Liberty Mid-Atlantic HIDTA; (4) Allegheny, Beaver, and Washington Counties in Pennsylvania and Butler County in Ohio as part of the Ohio HIDTA; and (5) Mineral County in West Virginia as part of the Washington/Baltimore HIDTA.
Appointment of Members of Senior Executive Service Performance Review Board
Document Number: 2018-18022
Type: Notice
Date: 2018-08-21
Agency: Executive Office of the President, National Drug Control Policy Office
The following persons have been appointed to the ONDCP Senior Executive Service Performance Review Board: Martha Gagne (as Chair), Michael Gottlieb, James Olson, and Kemp Chester.
Designation of Three High Intensity Drug Trafficking Areas
Document Number: 2018-09567
Type: Notice
Date: 2018-05-07
Agency: Executive Office of the President, National Drug Control Policy Office
The Director of the Office of National Drug Control Policy designated three areas as High Intensity Drug Trafficking Areas (HIDTA) pursuant to 21 U.S.C. 1706. These areas are the First, Third, and Fourth Judicial Districts of Alaska.
Notification of a Public Meeting of the President's Commission on Combating Drug Addiction and the Opioid Crisis (Commission)
Document Number: 2017-22343
Type: Notice
Date: 2017-10-16
Agency: Executive Office of the President, National Drug Control Policy Office
ONDCP announces the fifth meeting of the President's Commission on Combating Drug Addiction and the Opioid Crisis to advance the Commission's work on drug issues and the opioid crisis per Executive Order 13784. The meeting will consist of personal stories regarding addiction and discussion of and voting on the Commission's Final Report that will be posted on ONDCP's Commission Web site below shortly before the meeting.
Notification of a Public Meeting of the President's Commission on Combating Drug Addiction and the Opioid Crisis (Commission)
Document Number: 2017-21360
Type: Notice
Date: 2017-10-04
Agency: Executive Office of the President, National Drug Control Policy Office
ONDCP announces the fourth meeting of the President's Commission on Combating Drug Addiction and the Opioid Crisis to advance the Commission's work on drug issues and the opioid crisis per Executive Order 13784. The meeting will consist of discussion regarding insurance issues related to the opioid epidemic.
Designation of 16 Counties as High Intensity Drug Trafficking Areas
Document Number: 2017-20937
Type: Notice
Date: 2017-09-29
Agency: Executive Office of the President, National Drug Control Policy Office
The Director of the Office of National Drug Control Policy designated 16 additional counties/cities and removed two counties as High Intensity Drug Trafficking Areas (HIDTAs) pursuant to agency law.
Notification of a Public Meeting of the President's Commission on Combating Drug Addiction and the Opioid Crisis (Commission)
Document Number: 2017-19186
Type: Notice
Date: 2017-09-11
Agency: Executive Office of the President, National Drug Control Policy Office
ONDCP announces the third meeting of the President's Commission on Combating Drug Addiction and the Opioid Crisis to advance the Commission's work on drug issues and the opioid crisis per Executive Order 13784. The meeting will consist of statements to the Commission from invited government, nonprofit, and business organizations regarding Innovative Pain Management and Prevention Measures for Diversion followed by discussion of the issues raised.
Appointment of Members of Senior Executive Service Performance Review Board
Document Number: 2017-17689
Type: Notice
Date: 2017-08-22
Agency: Executive Office of the President, National Drug Control Policy Office
The following persons have been appointed to the ONDCP Senior Executive Service Performance Review Board: Dr. Terry Zobeck (as Chair), Mr. Michael Gottlieb, Ms. Michele Marx, and Mr. Kemp Chester.
Rescheduling Notification of the Public Teleconference of the President's Commission on Combating Drug Addiction and the Opioid Crisis (Commission)
Document Number: 2017-14835
Type: Notice
Date: 2017-07-14
Agency: Executive Office of the President, National Drug Control Policy Office
ONDCP is issuing this notice to advise the public that the Commission is rescheduling the teleconference of the President's Commission on Combating Drug Addiction and the Opioid Crisis that was previously scheduled for Monday, July 17th at 4 p.m. EST. The purpose of the meeting is to review a draft interim report that will be posted on ONDCP's Commission Web site listed below before the teleconference.
Notification of a Public Teleconference of the President's Commission on Combating Drug Addiction and the Opioid Crisis (Commission)
Document Number: 2017-13650
Type: Notice
Date: 2017-06-29
Agency: Executive Office of the President, National Drug Control Policy Office
ONDCP announces a meeting by teleconference of the President's Commission on Combating Drug Addiction and the Opioid Crisis. The purpose of the meeting is to review a draft interim report that will be posted on ONDCP's Commission Web site listed below before the teleconference.
Cancellation Notification of the Public Teleconference of the President's Commission on Combating Drug Addiction and the Opioid Crisis (Commission)
Document Number: 2017-13183
Type: Notice
Date: 2017-06-23
Agency: Executive Office of the President, National Drug Control Policy Office
ONDCP is issuing this notice to advise the public that the Commission is cancelling the teleconference of the President's Commission on Combating Drug Addiction and the Opioid Crisis that was previously scheduled for Monday, June 26th at 4 p.m. EST. Please check the Commission's Web site or future Federal Register notices for information about when this meeting will be rescheduled.
Notification of a Public Teleconference of the President's Commission on Combating Drug Addiction and the Opioid Crisis (Commission)
Document Number: 2017-12023
Type: Notice
Date: 2017-06-09
Agency: National Drug Control Policy Office, Executive Office of the President
ONDCP announces a meeting by teleconference of the President's Commission on Combating Drug Addiction and the Opioid Crisis. The purpose of the meeting is to review a draft interim report that will be posted on ONDCP's Commission Web site listed below before the teleconference.
Notification of a Public Meeting of the President's Commission on Combating Drug Addiction and the Opioid Crisis (Commission)
Document Number: 2017-11230
Type: Notice
Date: 2017-05-31
Agency: Executive Office of the President, National Drug Control Policy Office
ONDCP announces the first meeting of the President's Commission on Combating Drug Addiction and the Opioid Crisis to advance the Commission's work on drug issues and the opioid crisis per Executive Order 13784. The first meeting will consist of statements to the Commission from invited nonprofit organizations regarding drug issues followed by discussion of the issues raised.
Designation of Two Counties as High Intensity Drug Trafficking Areas
Document Number: 2016-09230
Type: Notice
Date: 2016-04-21
Agency: Executive Office of the President, National Drug Control Policy Office
The Director of the Office of National Drug Control Policy designated two additional counties as High Intensity Drug Trafficking Areas (HIDTA) pursuant to 21 U.S.C. 1706. The new counties are Austin and Walker Counties in Texas as part of the Houston HIDTA.
Designation of 14 Counties as High Intensity Drug Trafficking Areas
Document Number: 2016-04291
Type: Notice
Date: 2016-02-29
Agency: Executive Office of the President, National Drug Control Policy Office
The Director of the Office of National Drug Control Policy designated 14 additional counties as High Intensity Drug Trafficking Areas (HIDTA) pursuant to 21 U.S.C. 1706. The new counties are (1) Blount County, Tennessee and Carroll and Grayson Counties (including the Independent City of Galax) in Virginia as part of the Appalachia HIDTA; (2) Escambia and Santa Rosa Counties in Florida as part of the Gulf Coast HIDTA; (3) Muskegon County, Michigan as part of the Michigan HIDTA; (4) Bristol County, Massachusetts as part of the New England HIDTA; (5) Broome and Ulster Counties in New York as part of the New York/New Jersey HIDTA; (6) Linn County, Oregon as part of the Oregon- Idaho HIDTA; (7) McIntosh and Pittsburg Counties in Oklahoma as part of the Texoma HIDTA; (8) Carroll County, Maryland and Jefferson County, West Virginia as part of the Washington/Baltimore HIDTA.
Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards
Document Number: 2015-24114
Type: Rule
Date: 2015-09-23
Agency: Executive Office of the President, National Drug Control Policy Office
The Office of National Drug Control Policy (ONDCP), Executive Office of the President, finalizes its portion of the uniform Federal assistance rule published by the Office of Management and Budget, in the Federal Register on December 19, 2014.
Designation of County as High Intensity Drug Trafficking Area
Document Number: 2015-06771
Type: Notice
Date: 2015-03-25
Agency: Executive Office of the President, National Drug Control Policy Office
The Director of the Office of National Drug Control Policy designated 1 additional county as a High Intensity Drug Trafficking Area (HIDTA) pursuant to 21 U.S.C. 1706. The new county is New Castle County, Delaware as part of the Philadelphia/Camden HIDTA.
Paperwork Reduction Act; Proposed Collection; Comment Request
Document Number: 2015-06616
Type: Notice
Date: 2015-03-24
Agency: National Drug Control Policy Office, Executive Office of the President
In accordance with the Paperwork Reduction Act of 1995 (Pub. L. 104-13, 44 U.S.C. Chapter 35), the Office of National Drug Control Policy (ONDCP) announces it will submit to the Office of Management and Budget (OMB) Office of Information and Regulatory Affairs (OIRA) an information collection request for processing under 5 CFR 1320.10. The purpose of this notice is to allow for an additional 30 days of public comment.
Federal Awarding Agency Regulatory Implementation of Office of Management and Budget's Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards
Document Number: 2014-28697
Type: Rule
Date: 2014-12-19
Agency: Agency for International Development, Agencies and Commissions, Department of the Interior, Department of Justice, Department of Labor, National Aeronautics and Space Administration, National Archives and Records Administration, National Science Foundation, Small Business Administration, Social Security Administration, Department of State, Department of Transportation, Department of Treasury, Department of Veterans Affairs, National Institute of Food and Agriculture, National Endowment for the Arts, Office of the Chief Financial Officer, National Endowment for the Humanities, Institute of Museum and Library Services, Department of Housing and Urban Development, Department of Homeland Security, Department of Agriculture, Commodity Credit Corporation, Farm Service Agency, Rural Business-Cooperative Service, Rural Housing Service, Rural Utilities Service, Department of Commerce, Corporation for National and Community Service, Department of Defense, Department of Education, Department of Energy, Environmental Protection Agency, Executive Office of the President, Management and Budget Office, National Drug Control Policy Office, Federal Emergency Management Agency, Department of Health and Human Services
This joint interim final rule implements for all Federal award-making agencies the final guidance Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance) published by the Office of Management and Budget (OMB) on December 26, 2013. This rule is necessary in order to incorporate into regulation and thus bring into effect the Uniform Guidance as required by OMB. Implementation of this guidance will reduce administrative burden and risk of waste, fraud, and abuse for the approximately $600 billion per year awarded in Federal financial assistance. The result will be more Federal dollars reprogrammed to support the mission, new entities able to compete and win awards, and ultimately a stronger framework to provide key services to American citizens and support the basic research that underpins the United States economy.
Paperwork Reduction Act; Proposed Collection; Comment Request
Document Number: 2014-28273
Type: Notice
Date: 2014-12-01
Agency: National Drug Control Policy Office, Executive Office of the President
The Office of National Drug Control Policy (ONDCP) intends to submit the following information collection request to the Office of Management and Budget for review and approval under the Paperwork Reduction Act of 1995 (Pub. L. 104-13, 44 U.S.C. Chapter 35).
Removal of 5 Counties as High Intensity Drug Trafficking Areas
Document Number: 2014-25994
Type: Notice
Date: 2014-11-03
Agency: Executive Office of the President, National Drug Control Policy Office
The Director of the Office of National Drug Control Policy (ONDCP) removed 5 counties as High Intensity Drug Trafficking Areas (HIDTA) counties pursuant to 21 U.S.C. 1706, effective September 29, 2014. The 5 counties removed from HIDTA county designation within the Appalachia HIDTA are (1) Cumberland and Clinton Counties in Kentucky; (2) Clay and White Counties in Tennessee; and (3) Mason County in West Virginia. The Executive Board of the Appalachia HIDTA requested removal of these counties from designation after assessing the threat and determining that these counties no longer met the statutory criteria necessary for designation as HIDTA counties. ONDCP evaluated and accepted the request.
Notice of HIDTA Designations
Document Number: 2014-24176
Type: Notice
Date: 2014-10-10
Agency: National Drug Control Policy Office, Executive Office of the President
The Director of the Office of National Drug Control Policy designated 26 additional counties/cities as High Intensity Drug Trafficking Areas (HIDTA) pursuant to 21 U.S.C. 1706. The new counties/ cities are (1) Madison and Nelson Counties in Kentucky, Tazewell County in Virginia, and Harrison County in West Virginia as part of the Appalachia HIDTA; (2) Pasco County in Florida as part of the Central Florida HIDTA; (3) Trinity and Siskiyou Counties in California as part of the Central Valley California HIDTA; (4) Brazoria County in Texas as part of the Houston HIDTA; (5) Rockingham County in New Hampshire as part of the New England HIDTA; (6) Chautauqua, Dutchess, Putnam, and Rockland Counties in New York as part of the New York/New Jersey HIDTA; (7) Ada and Canyon Counties in Idaho, and Malheur County in Oregon as part of the Oregon HIDTA; (8) Gallatin County in Montana as part of the Rocky Mountain HIDTA; (9) Potter and Randall Counties in Texas as part of the Texoma HIDTA; and (10) Berkeley County in West Virginia and the Cities of Chesapeake, Hampton, Newport News, Norfolk, Portsmouth, and Virginia Beach in Virginia as part of the Washington/Baltimore HIDTA.
Appointment of Members of Senior Executive Service Performance Review Board
Document Number: 2014-21121
Type: Notice
Date: 2014-09-05
Agency: National Drug Control Policy Office, Executive Office of the President
The following persons have been appointed to the ONDCP Senior Executive Service Performance Review Board: Dr. Terry Zobeck (as Chair), Mr. Gerard Burns, Ms. Michele Marx, and Mr. Jeffrey Teitz.
Summit on Heroin and Prescription Drugs: Federal, State, and Community Responses
Document Number: 2014-13912
Type: Notice
Date: 2014-06-16
Agency: National Drug Control Policy Office, Executive Office of the President
The Office of National Drug Control Policy (ONDCP) will host a ``Summit on Heroin and Prescription Drugs: Federal, State, and Community Responses'' highlighting the public health and safety issues surrounding prescription painkillers and heroin. The conference will be held from 9 a.m. to 12:30 p.m. on Thursday, June 19, 2014 in the South Court Auditorium of the Eisenhower Executive Office Building, 17th Street and Pennsylvania Avenue NW., Washington, DC 20500. While the summit is not open to the general public, it will be streamed live on- line for the general public to view on www.WhiteHouse.gov/Live. The goal of the summit is to discuss trends and challenges in the epidemic of opioid abuse in the United States, identify innovative practices and models, and discuss how practitioners at every level can help reduce overdose deaths and public health consequences. Participants will include Attorney General Eric Holder, Vermont Governor Peter Shumlin, National Institute on Drug Abuse Director Dr. Nora Volkow, and experts from across the country on education, treatment, and overdose and infectious disease prevention. Summit participants will not be deliberating or providing consensus advice or recommendations to ONDCP. Issues explored will include expanding drug treatment access to millions through the Affordable Care Act, encouraging people and medical professionals to learn the signs and symptoms of problematic drug use and to intervene before substance use becomes a chronic condition, and supporting the use of naloxone, an overdose reversal drug that's easy to administer and has already saved thousands of lives.
Designation of Thirteen Counties as High Intensity Drug Trafficking Areas
Document Number: 2014-01089
Type: Notice
Date: 2014-01-22
Agency: National Drug Control Policy Office, Executive Office of the President
The Director of the Office of National Drug Control Policy designated thirteen additional counties as High Intensity Drug Trafficking Areas pursuant to 21 U.S.C. 1706. The new counties are (1) Bradley County in Tennessee, Dickenson County in Virginia, and Wyoming and Raleigh Counties in West Virginia as part of the Appalachia HIDTA; (2) Rockingham County in North Carolina, and Florence and Horry Counties in South Carolina as part of the Atlanta-Carolinas HIDTA (formerly known as ``Atlanta HIDTA''); (3) Forrest County in Mississippi as part of the Gulf Coast HIDTA; (4) Williams County in North Dakota as part of the Midwest HIDTA; (5) Humboldt County in California as part of the Northern California HIDTA; and (6) Cecil and Frederick Counties in Maryland and Roanoke County in Virginia as part of the Washington/Baltimore HIDTA.
Technology Innovations for Substance Abuse and Mental Health Treatment Conference & Related Health Information Technology (HIT) Meeting
Document Number: 2013-21213
Type: Notice
Date: 2013-08-30
Agency: National Drug Control Policy Office, Executive Office of the President
The Office of National Drug Control Policy (ONDCP) and the Substance Abuse and Mental Health Administration (SAMHSA) in partnership with the Office of the National Coordinator for Health Information Technology, and the National Institutes of Health's Office of Behavioral and Social Sciences Research, will host a Technology Innovations for Substance Abuse and Mental Health Treatment Conference highlighting promising innovations for treating these disorders. This conference will bring together innovators in technology and health care experts promoting the dissemination of innovative, evidence-based technologies that advance prevention, treatment, and recovery for these disorders. The conference will be held on September 16, 2013 from 8:00 a.m. to 5:00 p.m. in the South Court Auditorium, Eisenhower Executive Office Building, 17th Street and Pennsylvania Avenue NW., Washington DC, 20500. The goal of this conference is to highlight advances in health information technologies (HIT) for behavioral health, and promote technology advances and dissemination of evidence-based tools that address patient safety and the advancement of successful prevention, treatment and recovery. The specific conference objectives are to: (1) Promote evidence-based tools to advance treatment of substance use and mental health disorders; (2) advance the Administration's 2010 National Drug Control Strategy blueprint and the HIT initiatives at SAMHSA and the Office of the National Coordinator; and (3) encourage the use of technologies to improve health, improve quality of care, and increase patient engagement. On Tuesday, September 17, SAMHSA and ONDCP are holding a smaller meeting with state representatives and health system administrators on HIT systems to discuss technical issues and obtain experiential and anecdotal information from each of the attendees. This group will not be deliberating or providing consensus advice or recommendations to SAMHSA or ONDCP. The meeting will be held 9:00 a.m. to 1:00 p.m. in the 5th Floor Conference Room of ONDCP at 750 17th Street NW., Washington DC, 20503. Members of the public who wish to attend on either day are required to call ONDCP's Technology Innovations for Substance Abuse and Mental Health Treatment Conference telephone line at (202) 395-5696 to reserve a seat and arrange building access by no later than Monday, September 9, 2013. Seating for members of the public is limited and will be assigned on a first call, first served basis. The September 16 conference will be live-streamed on-line for members of the public who wish to observe, and conference material will be available to the public following the meeting. Go to http://www.whitehouse.gov/ondcp for more information. To Attend or For Further Information Contact: June Sivilli at (202) 395-5696 or email rsvpITSept16@ondcp.eop.gov.
Appointment of Members of Senior Executive Services Performance Review Board
Document Number: 2013-12248
Type: Notice
Date: 2013-05-23
Agency: National Drug Control Policy Office, Executive Office of the President
The following persons have been appointed to the ONDCP Senior Executive Service Performance Review Board: Mr. Jeffrey Teitz, Dr. Terry Zobeck, Ms. Martha Gagne, and Mr. Gerard Burns.
Paperwork Reduction Act; 30-Day Notice
Document Number: 2013-08154
Type: Notice
Date: 2013-04-09
Agency: National Drug Control Policy Office, Executive Office of the President
Paperwork Reduction Act; 30-Day Notice
Document Number: 2013-06792
Type: Notice
Date: 2013-03-26
Agency: National Drug Control Policy Office, Executive Office of the President
Paperwork Reduction Act; Notice of Intent To Collect; Comment Request
Document Number: 2013-01762
Type: Notice
Date: 2013-01-29
Agency: National Drug Control Policy Office, Executive Office of the President
ONDCP proposes the extension of three existing data collection instruments used in the production of advertising for the National Youth Anti-Drug Media Campaign and for advertising tracking. Purpose: The existing data collection instruments are critical to the continuity and improvement of the National Youth Anti-Drug Media Campaign. Type and Title of Collections: Qualitative Research, OMB 3201-0011, uses focus groups. Copy Testing, OMB 3201-0006, consists of 15-minute online interviews. Tracking Study, OMB 3201-0010, consists of 15-minute online interviews. Frequency: Qualitative Research and Copy Testing performed quarterly. Tracking Study performed weekly. Affected Public: Teenagers and adult influencers of teenagers. Estimated Burden: Qualitative Research, $19,800; Copy Testing, $16,500; Tracking Study, $37,700. Additional information: Collection instruments similar to those proposed are available at the Information Collection Review section of http://www.reginfo.gov/public/jsp/Utilities/index.jsp. Contact: Address comments or questions to Andrew Hertzberg through any of the following: Executive Office of the President, Office of National Drug Control Policy, Washington DC 20503; AHertzberg@ondcp.eop.gov; (202) 395-6721 (fax); or, (202) 395-6353 (voice).
Information Collection; Paperwork Reduction Act; 60-Day Notice
Document Number: 2013-00857
Type: Notice
Date: 2013-01-17
Agency: National Drug Control Policy Office, Executive Office of the President
Appointment of Members of Senior Executive Services Performance Review Board
Document Number: 2012-23281
Type: Notice
Date: 2012-09-21
Agency: National Drug Control Policy Office, Executive Office of the President
The following persons have been appointed to the ONDCP Senior Executive Service Performance Review Board: Mr. Jeffery J. Teitz, Ms. Martha Gagne, Mr. Robert W. Denniston, and Ms. Michelle C. Marx.
Revised Meeting Notice: Leadership Meeting on Maternal, Fetal, and Infant Opioid Exposure and Neonatal Abstinence Syndrome
Document Number: 2012-18488
Type: Notice
Date: 2012-07-30
Agency: National Drug Control Policy Office, Executive Office of the President
An ONDCP Leadership Meeting on Maternal, Fetal and Infant Opioid Exposure and Neonatal Abstinence Syndrome (NAS) will bring together leaders in the field of policy, opioid exposed infants, pain treatment during pregnancy, and addiction treatment during and after pregnancy. The meeting will be held on Thursday, August 30th 2012 in the Indian Treaty Room, Eisenhower Executive Office Building, 17th Street and Pennsylvania Avenue NW., Washington D.C, 20500 starting at 9:00 a.m. and concluding at 5:30 p.m. The overall objectives of the meeting are to review the state of science and policy and discuss the remaining challenges to the field concerning the upswing in maternal prescription drug abuse and dependence and resulting increases in opioid exposed babies with NAS and possibly other consequences. Misuse and abuse of, and dependence upon, prescription opioid drugs adversely affect the health of millions of Americans and their families. The specific conference objectives are: (1) To share research findings concerning the NAS epidemic and its costs; (2) to begin a national discussion concerning promising and best practices for treating opioid exposed babies; (3) to raise awareness about opioid misuse and dependence during pregnancy and the need for women with drug use disorders to access treatment through family medicine and gynecological practitioners, and specialty treatment providers; (4) to discuss legal and policy issues related to opioid using pregnant women and mothers including barriers to accessing treatment; (5) to promote awareness among regulatory agencies and insurers concerning the risks and benefits of opioids to developing fetuses and the likelihood of neonatal abstinence syndrome resulting from long term opioid use during pregnancy; and (6) to raise awareness about risk prevention opportunities among practitioners and regulators. Members of the public who wish to attend this meeting should telephone ONDCP's Maternal, Fetal, and Infant Opioid Exposure and Neonatal Abstinence Syndrome telephone line at (202) 395-7454 to arrange building access no later than Friday, August 10, 2012. Seating for members of the public is limited and will be assigned on a first come, first served basis. To Attend or For Further Information Contact: Cecelia Spitznas, Ph.D. at (202) 395-7454 or email rsvp@ondcp.eop.gov.
Leadership Meeting on Maternal, Fetal, and Infant Opioid Exposure and Neonatal Abstinence Syndrome
Document Number: 2012-17679
Type: Notice
Date: 2012-07-20
Agency: National Drug Control Policy Office, Executive Office of the President
An ONDCP Leadership Meeting on Maternal, Fetal and Infant Opioid Exposure and Neonatal Abstinence Syndrome (NAS) will bring together leaders in the field of policy, opioid exposed infants, pain treatment during pregnancy, and addiction treatment during and after pregnancy. The meeting will be held on Thursday, August 30th 2012 at the White House Conference Center at 726 Jackson Place, NW., Washington D.C., starting at 9:00 a.m. and concluding at 5:30 p.m. The overall objectives of the meeting are to review the state of science and policy and discuss the remaining challenges to the field concerning the upswing in maternal prescription drug abuse and dependence and resulting increases in opioid exposed babies with NAS and possibly other consequences. Misuse and abuse of, and dependence upon, prescription opioid drugs adversely affect the health of millions of Americans and their families. The specific conference objectives are: (1) To share research findings concerning the NAS epidemic and its costs; (2) to begin a national discussion concerning promising and best practices for treating opioid exposed babies; (3) to raise awareness about opioid misuse and dependence during pregnancy and the need for women with drug use disorders to access treatment through family medicine and gynecological practitioners, and specialty treatment providers; (4) to discuss legal and policy issues related to opioid using pregnant women and mothers including barriers to accessing treatment; (5) to promote awareness among regulatory agencies and insurers concerning the risks and benefits of opioids to developing fetuses and the likelihood of neonatal abstinence syndrome resulting from long term opioid use during pregnancy; and (6) to raise awareness about risk prevention opportunities among practitioners and regulators. Members of the public who wish to attend the meeting should telephone ONDCP's Maternal, Fetal, and Infant Opioid Exposure and Neonatal Abstinence Syndrome telephone line at (202) 395-7454 to arrange building access. To Attend or For Further Information Contact: Cecelia Spitznas, Ph.D. at (202) 395-7454 or email rsvp@ondcp.eop.gov.